Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
3.260
-0.060 (-1.81%)
Jul 10, 2026, 11:30 AM EDT - Market open
Alvotech Revenue
Alvotech had revenue of $105.87M in the quarter ending March 31, 2026, a decrease of -20.29%. This brings the company's revenue in the last twelve months to $559.38M, down -4.48% year-over-year. In the year 2025, Alvotech had annual revenue of $586.32M with 19.74% growth.
Revenue (ttm)
$559.38M
Revenue Growth
-4.48%
P/S Ratio
2.11
Revenue / Employee
$439,439
Employees
1,279
Market Cap
1.16B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 586.32M | 96.64M | 19.74% |
| Dec 31, 2024 | 489.68M | 398.25M | 435.56% |
| Dec 31, 2023 | 91.43M | 6.41M | 7.54% |
| Dec 31, 2022 | 85.03M | 48.26M | 131.23% |
| Dec 31, 2021 | 36.77M | -29.84M | -44.80% |
| Dec 31, 2020 | 66.62M | 34.70M | 108.71% |
| Dec 31, 2019 | 31.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| Trulieve Cannabis | 1.17B |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 796.33M |
| Pacira BioSciences | 734.86M |
| Xeris Biopharma Holdings | 314.85M |
| Harrow | 268.68M |
ALVO News
- 6 days ago - Transactions of Managers and Closely Associated Persons - GlobeNewsWire
- 9 days ago - Alvotech further strengthens liquidity by securing term loan facility of $75 million - GlobeNewsWire
- 22 days ago - Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement - GlobeNewsWire
- 22 days ago - Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares - GlobeNewsWire
- 24 days ago - Alvotech $152M Spot Secondary priced at $3.75 - TheFly
- 24 days ago - Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement - GlobeNewsWire
- 24 days ago - Alvotech TBA Spot Secondary; price range $3.75-$undefined - TheFly
- 24 days ago - Alvotech announces termination of ATM Prospectus Supplement with Jefferies - TheFly